Does the media favor BEAM or NTLA?

In the previous week, Beam Therapeutics had 9 more articles in the media than Intellia Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 5 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.93 beat Intellia Therapeutics' score of 0.56 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or NTLA?

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Intellia Therapeutics. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for Intellia Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.71 beat Intellia Therapeutics' score of 0.56 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NTLA or EDIT?

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 5 articles in the media. Editas Medicine's average media sentiment score of 1.08 beat Intellia Therapeutics' score of 0.56 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ERAS or NTLA?

In the previous week, Erasca had 30 more articles in the media than Intellia Therapeutics. MarketBeat recorded 35 mentions for Erasca and 5 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.56 beat Erasca's score of 0.23 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 6 Very Positive mention(s) 1 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Scholar Rock and 5 mentions for Intellia Therapeutics. Scholar Rock's average media sentiment score of 1.09 beat Intellia Therapeutics' score of 0.56 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Intellia Therapeutics (NTLA) Competitors

$11.18 +0.41 (+3.81%)

As of 12:59 PM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, ERAS, and SRRK

Should you buy Intellia Therapeutics stock or one of its competitors? MarketBeat compares Intellia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Erasca (ERAS), and Scholar Rock (SRRK).

How does Intellia Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Beam Therapeutics has a net margin of -39.66% compared to Intellia Therapeutics' net margin of -597.04%. Beam Therapeutics' return on equity of -29.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Beam Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	20.40	-$79.99M	-$0.68	N/A
Intellia Therapeutics	$67.67M	23.08	-$412.69M	-$3.54	N/A

Beam Therapeutics currently has a consensus target price of $46.85, suggesting a potential upside of 69.09%. Intellia Therapeutics has a consensus target price of $20.19, suggesting a potential upside of 80.57%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Beam Therapeutics had 9 more articles in the media than Intellia Therapeutics. MarketBeat recorded 14 mentions for Beam Therapeutics and 5 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.93 beat Intellia Therapeutics' score of 0.56 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Beam Therapeutics beats Intellia Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,448.10	-$581.60M	-$6.22	N/A
Intellia Therapeutics	$67.67M	23.08	-$412.69M	-$3.54	N/A

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Intellia Therapeutics. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for Intellia Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.71 beat Intellia Therapeutics' score of 0.56 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a net margin of -597.04% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

CRISPR Therapeutics presently has a consensus target price of $67.78, suggesting a potential upside of 28.61%. Intellia Therapeutics has a consensus target price of $20.19, suggesting a potential upside of 80.57%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CRISPR Therapeutics and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	23.08	-$412.69M	-$3.54	N/A
Editas Medicine	$40.52M	6.61	-$160.06M	-$1.23	N/A

Intellia Therapeutics presently has a consensus target price of $20.19, indicating a potential upside of 80.57%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 97.44%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 5 articles in the media. Editas Medicine's average media sentiment score of 1.08 beat Intellia Therapeutics' score of 0.56 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

Summary

Intellia Therapeutics and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Erasca has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Erasca had 30 more articles in the media than Intellia Therapeutics. MarketBeat recorded 35 mentions for Erasca and 5 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.56 beat Erasca's score of 0.23 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	6 Very Positive mention(s)	1 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Erasca's return on equity of -35.31% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

Erasca currently has a consensus target price of $21.64, suggesting a potential upside of 15.40%. Intellia Therapeutics has a consensus target price of $20.19, suggesting a potential upside of 80.57%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

Erasca has higher earnings, but lower revenue than Intellia Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Intellia Therapeutics	$67.67M	23.08	-$412.69M	-$3.54	N/A

Summary

Erasca and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Scholar Rock?

Intellia Therapeutics (NASDAQ:NTLA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Scholar Rock had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Scholar Rock and 5 mentions for Intellia Therapeutics. Scholar Rock's average media sentiment score of 1.09 beat Intellia Therapeutics' score of 0.56 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has lower revenue, but higher earnings than Intellia Therapeutics. Scholar Rock is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	23.08	-$412.69M	-$3.54	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Scholar Rock	N/A	-163.52%	-96.67%

Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Intellia Therapeutics currently has a consensus price target of $20.19, indicating a potential upside of 80.57%. Scholar Rock has a consensus price target of $56.21, indicating a potential upside of 17.35%. Given Intellia Therapeutics' higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Summary

Scholar Rock beats Intellia Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.56B	$3.54B	$6.81B	$12.94B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.15	7.33	279.92	25.45
Price / Sales	23.08	1,273.99	647.84	115.11
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.93	17.12	11.11	6.33
Net Income	-$412.69M	-$12.52M	$3.48B	$347.60M
7 Day Performance	2.66%	1.99%	2.04%	2.78%
1 Month Performance	-36.33%	-5.83%	-3.16%	-2.36%
1 Year Performance	-7.76%	50.13%	63.65%	20.74%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	3.3243 of 5 stars	$11.18 +3.8%	$20.19 +80.6%	-6.3%	$1.56B	$67.67M	N/A	600	Positive News Upcoming Earnings
BEAM Beam Therapeutics	2.5644 of 5 stars	$25.07 -0.1%	$46.85 +86.9%	+37.6%	$2.58B	$139.74M	N/A	510	News Coverage Earnings Report Gap Up
CRSP CRISPR Therapeutics	3.2915 of 5 stars	$46.73 +0.4%	$67.78 +45.0%	-11.6%	$4.51B	$1M	N/A	460	Trending News Earnings Report Upcoming Earnings Analyst Forecast
EDIT Editas Medicine	2.8842 of 5 stars	$2.68 +3.1%	$5.40 +101.5%	+8.6%	$262.39M	$38.69M	N/A	230	News Coverage Positive News Upcoming Earnings
ERAS Erasca	2.5424 of 5 stars	$18.87 -1.3%	$21.64 +14.7%	+1,183.5%	$5.87B	N/A	N/A	120	Trending News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, ERAS, and SRRK

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to Erasca?

Summary

How does Intellia Therapeutics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, ERAS, and SRRK

How does Intellia Therapeutics compare to Beam Therapeutics?

Is BEAM or NTLA more profitable?

Which has more volatility & risk, BEAM or NTLA?

Which has stronger valuation & earnings, BEAM or NTLA?

Do analysts rate BEAM or NTLA?

Does the media favor BEAM or NTLA?

Do insiders and institutionals hold more shares of BEAM or NTLA?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Which has higher valuation and earnings, CRSP or NTLA?

Does the media favor CRSP or NTLA?

Is CRSP or NTLA more profitable?

Which has more risk & volatility, CRSP or NTLA?

Do analysts recommend CRSP or NTLA?

Do institutionals and insiders hold more shares of CRSP or NTLA?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Which has stronger valuation and earnings, NTLA or EDIT?

Do analysts recommend NTLA or EDIT?

Does the media favor NTLA or EDIT?

Which has more risk and volatility, NTLA or EDIT?

Do institutionals & insiders have more ownership in NTLA or EDIT?

Is NTLA or EDIT more profitable?

Summary

How does Intellia Therapeutics compare to Erasca?

Which has more volatility and risk, ERAS or NTLA?

Do institutionals & insiders believe in ERAS or NTLA?

Does the media prefer ERAS or NTLA?

Is ERAS or NTLA more profitable?

Do analysts rate ERAS or NTLA?

Which has stronger earnings and valuation, ERAS or NTLA?

Summary

How does Intellia Therapeutics compare to Scholar Rock?

Does the media refer more to NTLA or SRRK?

Which has preferable earnings & valuation, NTLA or SRRK?

Is NTLA or SRRK more profitable?

Which has more volatility & risk, NTLA or SRRK?

Do insiders and institutionals have more ownership in NTLA or SRRK?

Do analysts recommend NTLA or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools